Truist initiated coverage of Protagonist Therapeutics with a Buy rating and $60 price target. The company’s lead asset rusfertide is a first-in-class drug targeting multi-billion rare blood cancer opportunities, supported by positive Phase 2 data and a pharma partnership, the analyst tells investors in a research note. The firm sees a favorable risk/reward for the shares over next 6-12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities
- Protagonist Therapeutics price target raised to $40 from $38 at H.C. Wainwright
- Protagonist Therapeutics sees cash runway through end of 2027
- Protagonist Therapeutics reports Q2 EPS (50c), consensus (60c)
- Protagonist Therapeutics announces publication of clinical data on JNJ-2113